Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment

Similar Items

• The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
  od: Dowell, J, i dr.
  Izdano: (2008)
• Dalbavancin safety in the phase 2/3 clinical development program
  od: Seltzer, E, i dr.
  Izdano: (2008)
• Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
  od: Seltzer, Ben
  Izdano: (2010)
• Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
  od: Tortorici, Michael A., i dr.
  Izdano: (2010)
• Dosage adjustment in renal insufficiency.
  od: Mawer, G E
  Izdano: (1982)